Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Study to Determine the Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults Aged 18 Years and Over

NCT03880474 is registered in ClinicalTrials.gov with Barinthus Biotherapeutics as lead sponsor.

NCT NCT03880474
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03880474 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Study to Determine the Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults Aged 18 Years and Over
Lead sponsor
Barinthus Biotherapeutics
Phase
Phase 2
Overall status
Terminated
Start date
March 18, 2019
Completion date
January 21, 2020
Enrollment
2,364 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

influenza